Interleukin-6 Receptor Antibodies for Modulating the Systemic Inflammatory Response After Out-of-Hospital Cardiac Arrest - a Randomized Clinical Trial

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 03 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

01 Dec 2024 Results (n=80) assessing early effects of tocilizumab on circulating levels of metabolites in comatose patients resuscitated from OHCA published in the Resuscitation
01 Mar 2023 Results of a preplanned substudy of the IMICA trial assessing the inflammatory response after out-of-hospital cardiac arrest (OHCA) is modulated by blocking IL-6-mediated signalling with tocilizumab, and to relate induced changes to clinical status, myocardial- and brain injury, published in the Resuscitation.
15 Nov 2021 Results of substudy assessing changes in cytokine levels induced by blocking the IL-6-mediated signaling with tocilizumab presented at the American Heart Association Scientific Sessions 2021

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com